A new sepsis drug developed by Australian researchers has shown promising results in a phase II clinical trial. The study included 180 patients. Carbohydrate-based treatment reduces sepsis by calming a dangerous immune response. This reaction can cause organ failure. There is currently no specific treatment available for sepsis. The findings represent a major step forward. Researchers are now preparing for Phase III trials.